12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1
Jeffrey M. Saland(Université Claude Bernard Lyon 1), John C. Lieske(Mayo Clinic), David J. Sas(Mayo Clinic), Georges Deschênes(Hôpital Robert-Debré), Michael J. Koren(Jacksonville Center for Clinical Research), Kenji P. Fujita, Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), John M. Gansner(Brigham and Women's Hospital), Wesley Hayes(Great Ormond Street Hospital), Daniel G. Fuster(University Hospital of Bern), Eva Šimková(Université Claude Bernard Lyon 1), Yaacov Frishberg(Shaare Zedek Medical Center), Sander F. Garrelfs(Emma Kinderziekenhuis), Jeffrey S. Overcash(San Diego Composites (United States)), Martin Coenen(University Hospital Bonn), Daniella Magen(Université Claude Bernard Lyon 1), Taylor Ngo(Boehringer Ingelheim (Germany)), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Sally A. Hulton(Birmingham Children's Hospital), Anne-Laure A. Sellier-Leclerc(Hospices Civils de Lyon), Jaap W. Groothoff(University of Amsterdam), Tracy L. McGregor(Université Claude Bernard Lyon 1), Kristin Meliambro(Icahn School of Medicine at Mount Sinai)
Cited by 4
Related Papers
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
|The Lancet|2019|785
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505